AZN vs GILD
AstraZeneca PLC and Gilead Sciences, both Healthcare
AstraZeneca PLC is the larger company at $245B against $187B. Over the past year GILD returned +34% against +3.2% for AZN. The RyuScore puts AZN ahead, 62 against 44 out of 100.
| Figure | AZN | GILD |
|---|---|---|
| Last close | $158 | $150 |
| Market cap | $245B | $187B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 26.1 | n/a |
| Dividend yield | n/a | 2.1% |
| 1-year return | +3.2% | +34% |
| 5-year return | +54% | +154% |
| RyuScoresector-relative, 1–10 | 62/100 | 44/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Gilead Sciences
Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.